Daniel P. Groom, Amanda Lopacinski, Scott J. Garforth and Vern L. Schramm*,
{"title":"新出现的抗癌靶点人adp -核糖基转移酶的动力学机制","authors":"Daniel P. Groom, Amanda Lopacinski, Scott J. Garforth and Vern L. Schramm*, ","doi":"10.1021/acs.biochem.5c0010510.1021/acs.biochem.5c00105","DOIUrl":null,"url":null,"abstract":"<p >Human ADP-ribosyltransferase 1 (<i>hs</i>ART1, EC: 2.4.2.31) is a membrane-associated GPI-anchored, arginine-specific, mono-ADP-ribosyltransferase. The enzyme resides on the endoplasmic reticulum and extracellular cell surface, where it catalyzes the transfer of ADP-ribose (ADPR) from NAD<sup>+</sup> to arginine residues of neighboring target proteins, forming free nicotinamide (NAM) and N-linked mono-ADP-ribosylation (MARylation) of the target protein. Arginine-specific MARylation regulates the target’s function and cellular roles. Dysregulation of <i>hs</i>ART1 activity has been shown to permit immune cell evasion in non-small cell lung cancer (NSCLC). Inhibition of <i>hs</i>ART1 decreases tumor efficacy and increases T-cell infiltration. <i>hs</i>ART1 is an emerging checkpoint target in select cancers. We performed the first kinetic characterization of the ADP-ribosyltransferase and NAD<sup>+</sup> glycohydrolase activities of <i>hs</i>ART1. Without an <span>l</span>-arginine substrate, <i>hs</i>ART1 slowly hydrolyses NAD<sup>+</sup> into NAM and ADPR through an ordered kinetic mechanism. NAD<sup>+</sup> binding and hydrolysis are followed by the ordered release of NAM followed by ADPR. The ADP-ribosyltransferase activity of <i>hs</i>ART1 to <span>l</span>-arginine-like small molecule substrates gives over a 100-fold improvement in <i>k</i><sub>cat</sub>/<i>K</i><sub>m</sub> and <i>k</i><sub>cat</sub> relative to NAD<sup>+</sup> hydrolysis. With ADP-ribose acceptors, <i>hs</i>ART1 proceeds through a partially ordered mechanism, whereby the substrate binding of NAD<sup>+</sup> and <span>l</span>-arginine-like substrate is random. Chemistry proceeds through a ternary complex, and product release is ordered, with NAM first, followed by the ADP-ribosylated acceptor. <i>hs</i>ART1 is not diffusionally rate-limited on <i>k</i><sub>cat</sub> and only partially limited on <i>k</i><sub>cat</sub>/<i>K</i><sub>m</sub> for <span>l</span>-arginine methyl ester. The detailed description of the kinetic mechanism of <i>hs</i>ART1 can aid in the development of novel and selective inhibitors.</p>","PeriodicalId":28,"journal":{"name":"Biochemistry Biochemistry","volume":"64 9","pages":"2077–2088 2077–2088"},"PeriodicalIF":2.9000,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Kinetic Mechanism of the Emergent Anticancer Target, Human ADP-ribosyltransferase 1\",\"authors\":\"Daniel P. Groom, Amanda Lopacinski, Scott J. Garforth and Vern L. Schramm*, \",\"doi\":\"10.1021/acs.biochem.5c0010510.1021/acs.biochem.5c00105\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Human ADP-ribosyltransferase 1 (<i>hs</i>ART1, EC: 2.4.2.31) is a membrane-associated GPI-anchored, arginine-specific, mono-ADP-ribosyltransferase. The enzyme resides on the endoplasmic reticulum and extracellular cell surface, where it catalyzes the transfer of ADP-ribose (ADPR) from NAD<sup>+</sup> to arginine residues of neighboring target proteins, forming free nicotinamide (NAM) and N-linked mono-ADP-ribosylation (MARylation) of the target protein. Arginine-specific MARylation regulates the target’s function and cellular roles. Dysregulation of <i>hs</i>ART1 activity has been shown to permit immune cell evasion in non-small cell lung cancer (NSCLC). Inhibition of <i>hs</i>ART1 decreases tumor efficacy and increases T-cell infiltration. <i>hs</i>ART1 is an emerging checkpoint target in select cancers. We performed the first kinetic characterization of the ADP-ribosyltransferase and NAD<sup>+</sup> glycohydrolase activities of <i>hs</i>ART1. Without an <span>l</span>-arginine substrate, <i>hs</i>ART1 slowly hydrolyses NAD<sup>+</sup> into NAM and ADPR through an ordered kinetic mechanism. NAD<sup>+</sup> binding and hydrolysis are followed by the ordered release of NAM followed by ADPR. The ADP-ribosyltransferase activity of <i>hs</i>ART1 to <span>l</span>-arginine-like small molecule substrates gives over a 100-fold improvement in <i>k</i><sub>cat</sub>/<i>K</i><sub>m</sub> and <i>k</i><sub>cat</sub> relative to NAD<sup>+</sup> hydrolysis. With ADP-ribose acceptors, <i>hs</i>ART1 proceeds through a partially ordered mechanism, whereby the substrate binding of NAD<sup>+</sup> and <span>l</span>-arginine-like substrate is random. Chemistry proceeds through a ternary complex, and product release is ordered, with NAM first, followed by the ADP-ribosylated acceptor. <i>hs</i>ART1 is not diffusionally rate-limited on <i>k</i><sub>cat</sub> and only partially limited on <i>k</i><sub>cat</sub>/<i>K</i><sub>m</sub> for <span>l</span>-arginine methyl ester. The detailed description of the kinetic mechanism of <i>hs</i>ART1 can aid in the development of novel and selective inhibitors.</p>\",\"PeriodicalId\":28,\"journal\":{\"name\":\"Biochemistry Biochemistry\",\"volume\":\"64 9\",\"pages\":\"2077–2088 2077–2088\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-04-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biochemistry Biochemistry\",\"FirstCategoryId\":\"1\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acs.biochem.5c00105\",\"RegionNum\":3,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemistry Biochemistry","FirstCategoryId":"1","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.biochem.5c00105","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Kinetic Mechanism of the Emergent Anticancer Target, Human ADP-ribosyltransferase 1
Human ADP-ribosyltransferase 1 (hsART1, EC: 2.4.2.31) is a membrane-associated GPI-anchored, arginine-specific, mono-ADP-ribosyltransferase. The enzyme resides on the endoplasmic reticulum and extracellular cell surface, where it catalyzes the transfer of ADP-ribose (ADPR) from NAD+ to arginine residues of neighboring target proteins, forming free nicotinamide (NAM) and N-linked mono-ADP-ribosylation (MARylation) of the target protein. Arginine-specific MARylation regulates the target’s function and cellular roles. Dysregulation of hsART1 activity has been shown to permit immune cell evasion in non-small cell lung cancer (NSCLC). Inhibition of hsART1 decreases tumor efficacy and increases T-cell infiltration. hsART1 is an emerging checkpoint target in select cancers. We performed the first kinetic characterization of the ADP-ribosyltransferase and NAD+ glycohydrolase activities of hsART1. Without an l-arginine substrate, hsART1 slowly hydrolyses NAD+ into NAM and ADPR through an ordered kinetic mechanism. NAD+ binding and hydrolysis are followed by the ordered release of NAM followed by ADPR. The ADP-ribosyltransferase activity of hsART1 to l-arginine-like small molecule substrates gives over a 100-fold improvement in kcat/Km and kcat relative to NAD+ hydrolysis. With ADP-ribose acceptors, hsART1 proceeds through a partially ordered mechanism, whereby the substrate binding of NAD+ and l-arginine-like substrate is random. Chemistry proceeds through a ternary complex, and product release is ordered, with NAM first, followed by the ADP-ribosylated acceptor. hsART1 is not diffusionally rate-limited on kcat and only partially limited on kcat/Km for l-arginine methyl ester. The detailed description of the kinetic mechanism of hsART1 can aid in the development of novel and selective inhibitors.
期刊介绍:
Biochemistry provides an international forum for publishing exceptional, rigorous, high-impact research across all of biological chemistry. This broad scope includes studies on the chemical, physical, mechanistic, and/or structural basis of biological or cell function, and encompasses the fields of chemical biology, synthetic biology, disease biology, cell biology, nucleic acid biology, neuroscience, structural biology, and biophysics. In addition to traditional Research Articles, Biochemistry also publishes Communications, Viewpoints, and Perspectives, as well as From the Bench articles that report new methods of particular interest to the biological chemistry community.